[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jona Hattangadi-Gluth\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100483520","longitudinal-prospective-study-of-neurocognition--neuroimaging-in-primary-bt-patients-100483520",false,"NCT05576103","Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients","Longitudinal Prospective Study of Neurocognitive Outcomes and Multimodal Quantitative Neuroimaging Outcomes in Primary Brain Tumor Patients Receiving Brain Radiotherapy","Inclusion Criteria:\n\n1. Patients 18 years or older\n2. Karnofsky performance status (KPS) ≥70\n3. Life expectancy of ≥1 year\n4. Primary brain tumor patients who will receive fractionated partial brain RT\n5. Able to complete neurocognitive assessments\n\nExclusion Criteria:\n\n1. Inability to undergo MRI with contrast\n2. Prior brain RT","ALL","18 Years","99 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired through this study to improve understanding of cognitive changes associated with radiation dosage to non-targeted tissue, and will provide the basis for evidence-based cognitive- sparing brain radiotherapy.",[25,26,27,28],"Primary Brain Tumor","Glioma","Meningioma","Schwannoma","RECRUITING","2026-06-09",{"date":32,"type":33},"2026-06-10","ACTUAL",{"date":35,"type":33},"2015-01",{"date":37,"type":21},"2030-12",{"name":39,"class":40},"Jona Hattangadi-Gluth","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100388846","phase-2-ucsd-image-guided-cognitive-sparing-radiosurgery-for-brain-metastases-100388846","NCT04343157","UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases","UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases: Avoidance of Eloquent White Matter and Hippocampal Regions","IG-SRS","Inclusion Criteria:\n\n1. Patients 18 years or older\n2. One to three brain metastases targets, all smaller than 3 cm in diameter (intact or resected tumor bed)\n3. Eastern cooperative Oncology Group (ECOG) performance status 0-2 (score of 0, no symptoms; 1, mild symptoms; 2, symptomatic, \\\u003C50% in bed during the day)\n4. Ability to answer questions and follow commands via neurocognitive testing\n5. Estimated life expectancy greater than 6 months\n6. Pathologic confirmation of extracerebral tumor site (eg, lung, breast, prostate) from either the primary site or a metastatic lesion\n7. Willingness\u002FAbility to undergo brain MRI scans\n8. Able to give informed consent\n\nExclusion Criteria:\n\n1. Pregnant or nursing women\n2. Women of childbearing potential unwilling to use adequate contraception\n3. Inability to complete a magnetic resonance imaging scan with contrast\n4. Tumor directly invading the critical area to be spared (for example a patient with tumor invading a critical white matter tract; ineligible for cognitive-sparing)\n5. Planned chemotherapy during SRS (on the day of SRS)\n6. Previous whole brain radiation therapy\n7. Leptomeningeal metastases (ineligible for SRS)\n8. Metastases from primary germ cell tumor, small cell carcinoma, or primary CNS lymphoma (ineligible for SRS)",{"count":51,"type":21},60,"INTERVENTIONAL",[54],"PHASE2","In this proposal, the investigators introduce advanced diffusion and volumetric imaging techniques along with innovative, automated image parcellation methods to identify critical brain regions, incorporate into cognitive-sparing SRS, and analyze biomarkers of radiation response. This work will advance the investigators' understanding of neurocognitive changes after brain SRS and help create interventions that preserve cognitive-function in brain metastases patients.",[57,58,59],"Brain Metastases, Adult","Neurocognitive Function","Cancer",{"date":32,"type":33},{"date":62,"type":33},"2019-05-01",{"date":64,"type":21},"2028-12-31",{"name":39,"class":40},""]